Basal insulin | OAD | p Value | |
---|---|---|---|
Number of patients | 75 | 75 | |
Gender, n (F/M) | 49/26 | 47/28 | 0.73 |
Age, years | 79±8 | 79±8.1 | 0.97 |
Race: black/white/other, n | 24/49/1 | 29/44/2 | 0.28 |
BMI, kg/m2 | 30±6 | 30±7 | 0.73 |
Diabetes duration, years | 8.6±4.9 | 7.7±5.2 | 0.15 |
HbA1C, % | 6.9±0.9 | 6.5±0.7 | 0.05 |
Previous diabetes therapy | 0.95 | ||
Metformin, n (%) | 19 (25) | 21 (28) | |
Sulfonylurea (SU), n (%) | 21 (28) | 20 (27) | |
DPP-4i, n (%) | 8 (11) | 6 (8) | |
Other, n (%) | 27 (36) | 28 (37) | |
Comorbidities | |||
Hypertension, n (%) | 68 (91) | 61 (81) | 0.16 |
Coronary heart disease, n (%) | 25 (36) | 22 (29) | 0.11 |
Heart failure, n (%) | 29 (39) | 21 (28) | 0.17 |
Acute kidney injury, n (%) | 21 (28) | 23 (31) | 0.72 |
Dyslipidemia, n (%) | 34 (45) | 33 (44) | 0.87 |
Dementia, n (%) | 27 (36) | 18 (24) | 0.11 |
Mental illness, n (%) | 33 (44) | 25 (33) | 0.18 |
Admission area | 0.99 | ||
Subacute Rehab | 70 (93) | 69 (92) | |
Long-term care | 5 (7) | 6 (8) |
HbA1C, glycated hemoglobin; BMI, body mass index.